dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Tolaney, Sara M |
dc.contributor.author | Punie, Kevin |
dc.contributor.author | Loirat, Delphine |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.contributor.author | Kalinsky, K. |
dc.contributor.author | Bardia, Aditya |
dc.date.accessioned | 2022-06-13T10:42:41Z |
dc.date.available | 2022-06-13T10:42:41Z |
dc.date.issued | 2021-09 |
dc.identifier.citation | Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148–56. |
dc.identifier.issn | 0923-7534 |
dc.identifier.uri | https://hdl.handle.net/11351/7666 |
dc.description | BRCA; Càncer de mama triple negatiu; Antigen 2 de la superfície cel·lular del trofoblast |
dc.description.sponsorship | This work was supported by Immunomedics, Inc., a subsidiary of Gilead Sciences, Inc. (no grant number). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Annals of Oncology;32(9) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Immunoglobulines - Ús terapèutic |
dc.subject | Marcadors bioquímics - Anàlisi |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Immunoconjugates |
dc.subject.mesh | /therapeutic use |
dc.title | Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.annonc.2021.06.002 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inmunoconjugados |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1016/j.annonc.2021.06.002 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Bardia A] Massachusetts General Hospital, Harvard Medical School, Boston, USA. [Tolaney SM] Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. [Punie K] Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. [Loirat D] Medical Oncology Department and D3i, Institut Curie, Paris, France. [Oliveira M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Kalinsky K] Columbia University Irving Medical Center, New York, USA. Winship Cancer Institute, Emory University, Atlanta, USA |
dc.identifier.pmid | 34116144 |
dc.identifier.wos | 000687824100010 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |